OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chase on the Presentation of Uterine Sarcomas

April 18th 2018

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the presentation of uterine sarcomas.

Dr. Kris on Combination Chemotherapy Approaches in NSCLC

April 18th 2018

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Hellmann on Tumor Mutational Burden in NSCLC

April 18th 2018

Matthew D. Hellmann, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role tumor mutational burden (TMB) plays in determining combination therapies for patients with non–small cell lung cancer (NSCLC).

Dr. Drilon on Targeted Therapies for Patients With ROS1-Rearranged Lung Cancer

April 18th 2018

Alexander Drilon, MD, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses targeted agents for patients with ROS1-rearranged lung cancer.

Dr. Rudin on Significance of the KEYNOTE-021 in Patients With NSCLC

April 17th 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the caveats of KEYNOTE-021.

Dr. Palmer on Molecular Abnormalities in Myeloproliferative Diseases

April 16th 2018

Jeanne M. Palmer, MD, hematologist oncologist, Mayo Clinic, discusses molecular abnormalities in myeloproliferative diseases, including polycythemia vera (PV) and the use of next-generation sequencing in identifying these mutations.

Dr. Willmott on Mechanisms of Resistance in Ovarian Cancer

April 16th 2018

Lyndsay J. Willmott, MD, gynecologic oncologist, Arizona Oncology, discusses the mechanisms of resistance to PARP inhibitors that have been identified in ovarian cancer.

Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC

April 16th 2018

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).

Dr. Mesa Discusses the Management of Patients With MPNs

April 14th 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the management of patients with myeloproliferative neoplasms.

Dr. Yu on the Importance of a Genetic Counselor in Prostate Cancer

April 14th 2018

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the importance of a genetic counselor in the treatment of patients with prostate cancer.

Dr. Andtbacka Discusses Next Steps With T-VEC in Melanoma

April 14th 2018

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the future of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.

Dr. Stewart on the Role of Transplant in Multiple Myeloma

April 13th 2018

Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.

Dr. Scribner on the Role of Chemotherapy in Ovarian Cancer

April 13th 2018

Dennis R. Scribner, MD, FACOG, FACS, clinical associate professor for the University of Arizona School of Medicine, Arizona Oncology, discusses the use of chemotherapy in patients with ovarian cancer.

Dr. Ross on the Unmet Needs in Uterine Carcinosarcoma

April 12th 2018

Malcolm Ross, MD, University of Pittsburgh, discusses unmet needs for patients with uterine carcinosarcoma.

Dr. Coutre Discusses Combination Strategies in ALL

April 12th 2018

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses combination strategies for the treatment of patients with acute lymphoblastic leukemia (ALL).

Dr. Blackwell on the Treatment of Young Women With Breast Cancer

April 12th 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the treatment of young women with breast cancer.

Dr. Bekaii-Saab on Napabucasin in Patients With Pancreatic Cancer

April 12th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential of napabucasin, previously known as BBI-608, in patients with pancreatic cancer.

Dr. Valdes-Albini on the FDA Approval of Adjuvant Pertuzumab in HER2+ Breast Cancer

April 12th 2018

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Verma Discusses Emerging Agents in HER2+ Breast Cancer

April 12th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses emerging agents for the treatment of HER2-positive breast cancer.

Dr. Chagpar on Surgery of the Primary Tumor in Metastatic Breast Cancer

April 12th 2018

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses surgery of the primary tumor in the metastatic setting of breast cancer.